At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 504 enrolled
Drug / intervention
LEO 90100 aerosol foam +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris
In Brief
A Phase 3 clinical trial evaluating LEO 90100 aerosol foam, Aerosol foam vehicle, and 2 other interventions for Psoriasis Vulgaris. Completed, enrolled 504 participants across 1 site.
Detailed Summary
The purpose is to compare the efficacy of treatment with LEO 90100 at Week 4 to that of calcipotriol plus betamethasone dipropionate (BDP) gel at Week 8 in subjects with psoriasis vulgaris
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartJun 2014
Primary CompletionFeb 2015
TodayJul 2026
First PostedMay 7, 2014
Enrollment StartJun 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.2 years ago
Interventions
LEO 90100 aerosol foamdrug
Aerosol foam vehicledrug
Calcipotriol BDP geldrug
Gel vehicledrug